Sunday, July 19, 2015 6:55:59 AM
To view the following table, try copying this info and pasting into notepad and adjusting the font. Hopefully (if there aren't any hard returns put in the table) you can view the table correctly.
Clearly not all placebo patients would count as an event (ie did NOT excerbate). If all placebo patients exacerbated, then there would have been no need to add 20 patients because the target would have been met. In the trial note that even though 20 patients were added the unblinding occured with "approximately one-half the number of patients ORIGINALLY targeted for enrollment."
So what would you get assuming different total trial patient population of (50,60,70,80,90,100) each with a target event of 1/2 the original target enrollment (25,30,35,40,45,50), assuming different Hazard Ratios (0,.05,.15,.20,.25,.30,.35,.40,.45,.50,.55,.60,.65,.70,.75,.80,.85,.90,.95, 1.00) and percentage Placebo Events (excacerbations) from 1% all the way through to
100% in 1% increments?
The one input i used was Target Events (ie 1/2 the patient population). This is the same number as the placebo patients and the same number as the gevo treated patients.
First Column= % placebo events from 1 to 100 by 1's
Second Column=Number of Placebos who excacerbated based on percentages listed in First Column
Third Column=at the top of the next 19 columns are the different hazard ratios and each calculated number in the column are the gevo events, these are calculated from the formula:
Hazard Ratio = gevokizumab events(exacerbations) divided by placebo events(exacerbations)
therefore,
gevokizumab events=Number Placebo events (from second column) multiplied by Hazard Rate at top of column
Note: if Placebo Events plus Gevo Events > Target events, then put a blank in the column entry.
For example here are the results for Target Events=30 (total patients=60) and assuming 1/3 of the placebo patients do NOT exacerbate (ie Placebo events=67%), the row would look like:
67,20.10,1.01,3.02,4.02,5.03,6.03,7.04,8.04,9.05 and the rest of the columns would be blank.
Now, assuming a 0.3 hazard ratio, the total exacerbations would be 20.10+6.03=26.13 or 26 patients, but you need 30 before you can unblind the data.
Anyway, draw your own conclusions.
Target Events = 30 data table below:
0.05 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
P-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events G-Events
1 0.30 0.02 0.05 0.06 0.08 0.09 0.11 0.12 0.14 0.15 0.17 0.18 0.20 0.21 0.23 0.24 0.26 0.27 0.29 0.30
2 0.60 0.03 0.09 0.12 0.15 0.18 0.21 0.24 0.27 0.30 0.33 0.36 0.39 0.42 0.45 0.48 0.51 0.54 0.57 0.60
3 0.90 0.05 0.14 0.18 0.23 0.27 0.32 0.36 0.41 0.45 0.50 0.54 0.59 0.63 0.68 0.72 0.77 0.81 0.86 0.90
4 1.20 0.06 0.18 0.24 0.30 0.36 0.42 0.48 0.54 0.60 0.66 0.72 0.78 0.84 0.90 0.96 1.02 1.08 1.14 1.20
5 1.50 0.08 0.23 0.30 0.38 0.45 0.53 0.60 0.68 0.75 0.83 0.90 0.98 1.05 1.13 1.20 1.28 1.35 1.43 1.50
6 1.80 0.09 0.27 0.36 0.45 0.54 0.63 0.72 0.81 0.90 0.99 1.08 1.17 1.26 1.35 1.44 1.53 1.62 1.71 1.80
7 2.10 0.11 0.32 0.42 0.53 0.63 0.74 0.84 0.95 1.05 1.16 1.26 1.37 1.47 1.58 1.68 1.79 1.89 2.00 2.10
8 2.40 0.12 0.36 0.48 0.60 0.72 0.84 0.96 1.08 1.20 1.32 1.44 1.56 1.68 1.80 1.92 2.04 2.16 2.28 2.40
9 2.70 0.14 0.41 0.54 0.68 0.81 0.95 1.08 1.22 1.35 1.49 1.62 1.76 1.89 2.03 2.16 2.30 2.43 2.57 2.70
10 3.00 0.15 0.45 0.60 0.75 0.90 1.05 1.20 1.35 1.50 1.65 1.80 1.95 2.10 2.25 2.40 2.55 2.70 2.85 3.00
11 3.30 0.17 0.50 0.66 0.83 0.99 1.16 1.32 1.49 1.65 1.82 1.98 2.15 2.31 2.48 2.64 2.81 2.97 3.14 3.30
12 3.60 0.18 0.54 0.72 0.90 1.08 1.26 1.44 1.62 1.80 1.98 2.16 2.34 2.52 2.70 2.88 3.06 3.24 3.42 3.60
13 3.90 0.20 0.59 0.78 0.98 1.17 1.37 1.56 1.76 1.95 2.15 2.34 2.54 2.73 2.93 3.12 3.32 3.51 3.71 3.90
14 4.20 0.21 0.63 0.84 1.05 1.26 1.47 1.68 1.89 2.10 2.31 2.52 2.73 2.94 3.15 3.36 3.57 3.78 3.99 4.20
15 4.50 0.23 0.68 0.90 1.13 1.35 1.58 1.80 2.03 2.25 2.48 2.70 2.93 3.15 3.38 3.60 3.83 4.05 4.28 4.50
16 4.80 0.24 0.72 0.96 1.20 1.44 1.68 1.92 2.16 2.40 2.64 2.88 3.12 3.36 3.60 3.84 4.08 4.32 4.56 4.80
17 5.10 0.26 0.77 1.02 1.28 1.53 1.79 2.04 2.30 2.55 2.81 3.06 3.32 3.57 3.83 4.08 4.34 4.59 4.85 5.10
18 5.40 0.27 0.81 1.08 1.35 1.62 1.89 2.16 2.43 2.70 2.97 3.24 3.51 3.78 4.05 4.32 4.59 4.86 5.13 5.40
19 5.70 0.29 0.86 1.14 1.43 1.71 2.00 2.28 2.57 2.85 3.14 3.42 3.71 3.99 4.28 4.56 4.85 5.13 5.42 5.70
20 6.00 0.30 0.90 1.20 1.50 1.80 2.10 2.40 2.70 3.00 3.30 3.60 3.90 4.20 4.50 4.80 5.10 5.40 5.70 6.00
21 6.30 0.32 0.95 1.26 1.58 1.89 2.21 2.52 2.84 3.15 3.47 3.78 4.10 4.41 4.73 5.04 5.36 5.67 5.99 6.30
22 6.60 0.33 0.99 1.32 1.65 1.98 2.31 2.64 2.97 3.30 3.63 3.96 4.29 4.62 4.95 5.28 5.61 5.94 6.27 6.60
23 6.90 0.35 1.04 1.38 1.73 2.07 2.42 2.76 3.11 3.45 3.80 4.14 4.49 4.83 5.18 5.52 5.87 6.21 6.56 6.90
24 7.20 0.36 1.08 1.44 1.80 2.16 2.52 2.88 3.24 3.60 3.96 4.32 4.68 5.04 5.40 5.76 6.12 6.48 6.84 7.20
25 7.50 0.38 1.13 1.50 1.88 2.25 2.63 3.00 3.38 3.75 4.13 4.50 4.88 5.25 5.63 6.00 6.38 6.75 7.13 7.50
26 7.80 0.39 1.17 1.56 1.95 2.34 2.73 3.12 3.51 3.90 4.29 4.68 5.07 5.46 5.85 6.24 6.63 7.02 7.41 7.80
27 8.10 0.41 1.22 1.62 2.03 2.43 2.84 3.24 3.65 4.05 4.46 4.86 5.27 5.67 6.08 6.48 6.89 7.29 7.70 8.10
28 8.40 0.42 1.26 1.68 2.10 2.52 2.94 3.36 3.78 4.20 4.62 5.04 5.46 5.88 6.30 6.72 7.14 7.56 7.98 8.40
29 8.70 0.44 1.31 1.74 2.18 2.61 3.05 3.48 3.92 4.35 4.79 5.22 5.66 6.09 6.53 6.96 7.40 7.83 8.27 8.70
30 9.00 0.45 1.35 1.80 2.25 2.70 3.15 3.60 4.05 4.50 4.95 5.40 5.85 6.30 6.75 7.20 7.65 8.10 8.55 9.00
31 9.30 0.47 1.40 1.86 2.33 2.79 3.26 3.72 4.19 4.65 5.12 5.58 6.05 6.51 6.98 7.44 7.91 8.37 8.84 9.30
32 9.60 0.48 1.44 1.92 2.40 2.88 3.36 3.84 4.32 4.80 5.28 5.76 6.24 6.72 7.20 7.68 8.16 8.64 9.12 9.60
33 9.90 0.50 1.49 1.98 2.48 2.97 3.47 3.96 4.46 4.95 5.45 5.94 6.44 6.93 7.43 7.92 8.42 8.91 9.41 9.90
34 10.20 0.51 1.53 2.04 2.55 3.06 3.57 4.08 4.59 5.10 5.61 6.12 6.63 7.14 7.65 8.16 8.67 9.18 9.69 10.20
35 10.50 0.53 1.58 2.10 2.63 3.15 3.68 4.20 4.73 5.25 5.78 6.30 6.83 7.35 7.88 8.40 8.93 9.45 9.98 10.50
36 10.80 0.54 1.62 2.16 2.70 3.24 3.78 4.32 4.86 5.40 5.94 6.48 7.02 7.56 8.10 8.64 9.18 9.72 10.26 10.80
37 11.10 0.56 1.67 2.22 2.78 3.33 3.89 4.44 5.00 5.55 6.11 6.66 7.22 7.77 8.33 8.88 9.44 9.99 10.55 11.10
38 11.40 0.57 1.71 2.28 2.85 3.42 3.99 4.56 5.13 5.70 6.27 6.84 7.41 7.98 8.55 9.12 9.69 10.26 10.83 11.40
39 11.70 0.59 1.76 2.34 2.93 3.51 4.10 4.68 5.27 5.85 6.44 7.02 7.61 8.19 8.78 9.36 9.95 10.53 11.12 11.70
40 12.00 0.60 1.80 2.40 3.00 3.60 4.20 4.80 5.40 6.00 6.60 7.20 7.80 8.40 9.00 9.60 10.20 10.80 11.40 12.00
41 12.30 0.62 1.85 2.46 3.08 3.69 4.31 4.92 5.54 6.15 6.77 7.38 8.00 8.61 9.23 9.84 10.46 11.07 11.69 12.30
42 12.60 0.63 1.89 2.52 3.15 3.78 4.41 5.04 5.67 6.30 6.93 7.56 8.19 8.82 9.45 10.08 10.71 11.34 11.97 12.60
43 12.90 0.65 1.94 2.58 3.23 3.87 4.52 5.16 5.81 6.45 7.10 7.74 8.39 9.03 9.68 10.32 10.97 11.61 12.26 12.90
44 13.20 0.66 1.98 2.64 3.30 3.96 4.62 5.28 5.94 6.60 7.26 7.92 8.58 9.24 9.90 10.56 11.22 11.88 12.54 13.20
45 13.50 0.68 2.03 2.70 3.38 4.05 4.73 5.40 6.08 6.75 7.43 8.10 8.78 9.45 10.13 10.80 11.48 12.15 12.83 13.50
46 13.80 0.69 2.07 2.76 3.45 4.14 4.83 5.52 6.21 6.90 7.59 8.28 8.97 9.66 10.35 11.04 11.73 12.42 13.11 13.80
47 14.10 0.71 2.12 2.82 3.53 4.23 4.94 5.64 6.35 7.05 7.76 8.46 9.17 9.87 10.58 11.28 11.99 12.69 13.40 14.10
48 14.40 0.72 2.16 2.88 3.60 4.32 5.04 5.76 6.48 7.20 7.92 8.64 9.36 10.08 10.80 11.52 12.24 12.96 13.68 14.40
49 14.70 0.74 2.21 2.94 3.68 4.41 5.15 5.88 6.62 7.35 8.09 8.82 9.56 10.29 11.03 11.76 12.50 13.23 13.97 14.70
50 15.00 0.75 2.25 3.00 3.75 4.50 5.25 6.00 6.75 7.50 8.25 9.00 9.75 10.50 11.25 12.00 12.75 13.50 14.25
51 15.30 0.77 2.30 3.06 3.83 4.59 5.36 6.12 6.89 7.65 8.42 9.18 9.95 10.71 11.48 12.24 13.01 13.77 14.54
52 15.60 0.78 2.34 3.12 3.90 4.68 5.46 6.24 7.02 7.80 8.58 9.36 10.14 10.92 11.70 12.48 13.26 14.04
53 15.90 0.80 2.39 3.18 3.98 4.77 5.57 6.36 7.16 7.95 8.75 9.54 10.34 11.13 11.93 12.72 13.52
54 16.20 0.81 2.43 3.24 4.05 4.86 5.67 6.48 7.29 8.10 8.91 9.72 10.53 11.34 12.15 12.96 13.77
55 16.50 0.83 2.48 3.30 4.13 4.95 5.78 6.60 7.43 8.25 9.08 9.90 10.73 11.55 12.38 13.20
56 16.80 0.84 2.52 3.36 4.20 5.04 5.88 6.72 7.56 8.40 9.24 10.08 10.92 11.76 12.60
57 17.10 0.86 2.57 3.42 4.28 5.13 5.99 6.84 7.70 8.55 9.41 10.26 11.12 11.97 12.83
58 17.40 0.87 2.61 3.48 4.35 5.22 6.09 6.96 7.83 8.70 9.57 10.44 11.31 12.18
59 17.70 0.89 2.66 3.54 4.43 5.31 6.20 7.08 7.97 8.85 9.74 10.62 11.51
60 18.00 0.90 2.70 3.60 4.50 5.40 6.30 7.20 8.10 9.00 9.90 10.80 11.70
61 18.30 0.92 2.75 3.66 4.58 5.49 6.41 7.32 8.24 9.15 10.07 10.98
62 18.60 0.93 2.79 3.72 4.65 5.58 6.51 7.44 8.37 9.30 10.23 11.16
63 18.90 0.95 2.84 3.78 4.73 5.67 6.62 7.56 8.51 9.45 10.40
64 19.20 0.96 2.88 3.84 4.80 5.76 6.72 7.68 8.64 9.60 10.56
65 19.50 0.98 2.93 3.90 4.88 5.85 6.83 7.80 8.78 9.75
66 19.80 0.99 2.97 3.96 4.95 5.94 6.93 7.92 8.91 9.90
67 20.10 1.01 3.02 4.02 5.03 6.03 7.04 8.04 9.05
68 20.40 1.02 3.06 4.08 5.10 6.12 7.14 8.16 9.18
69 20.70 1.04 3.11 4.14 5.18 6.21 7.25 8.28
70 21.00 1.05 3.15 4.20 5.25 6.30 7.35 8.40
71 21.30 1.07 3.20 4.26 5.33 6.39 7.46 8.52
72 21.60 1.08 3.24 4.32 5.40 6.48 7.56
73 21.90 1.10 3.29 4.38 5.48 6.57 7.67
74 22.20 1.11 3.33 4.44 5.55 6.66 7.77
75 22.50 1.13 3.38 4.50 5.63 6.75
76 22.80 1.14 3.42 4.56 5.70 6.84
77 23.10 1.16 3.47 4.62 5.78
78 23.40 1.17 3.51 4.68 5.85
79 23.70 1.19 3.56 4.74 5.93
80 24.00 1.20 3.60 4.80
81 24.30 1.22 3.65 4.86
82 24.60 1.23 3.69 4.92
83 24.90 1.25 3.74 4.98
84 25.20 1.26 3.78
85 25.50 1.28 3.83
86 25.80 1.29 3.87
87 26.10 1.31
88 26.40 1.32
89 26.70 1.34
90 27.00 1.35
91 27.30 1.37
92 27.60 1.38
93 27.90 1.40
94 28.20 1.41
95 28.50 1.43
96 28.80
97 29.10
98 29.40
99 29.70
100 30.00
Recent XOMA News
- XOMA Royalty Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 03/18/2026 08:30:00 PM
- XOMA shares climb after Q4 results top forecasts on strong royalty income • IH Market News • 03/18/2026 02:14:34 PM
- XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements • GlobeNewswire Inc. • 03/18/2026 10:00:00 AM
- XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 • GlobeNewswire Inc. • 03/12/2026 10:30:00 AM
- XOMA Royalty to Present at Investor Conferences in March • GlobeNewswire Inc. • 02/18/2026 09:30:00 PM
- XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. • GlobeNewswire Inc. • 02/09/2026 02:53:00 PM
- XOMA Royalty Announces CFO Transition • GlobeNewswire Inc. • 01/12/2026 12:30:00 PM
- XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab • GlobeNewswire Inc. • 12/30/2025 12:30:00 PM
- XOMA Royalty Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 12/22/2025 12:30:00 PM
- XOMA Royalty Enters into Agreement to Acquire Generation Bio • GlobeNewswire Inc. • 12/15/2025 10:00:00 PM
- XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc • GlobeNewswire Inc. • 12/05/2025 02:00:00 PM
- Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition • GlobeNewswire Inc. • 12/05/2025 12:45:00 PM
- Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty • GlobeNewswire Inc. • 11/26/2025 02:00:00 PM
- XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. • GlobeNewswire Inc. • 11/21/2025 12:45:00 PM
- XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements • GlobeNewswire Inc. • 11/12/2025 12:30:00 PM
- LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline • GlobeNewswire Inc. • 11/10/2025 09:09:25 PM
- Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty • GlobeNewswire Inc. • 10/24/2025 08:25:31 PM
- XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement • GlobeNewswire Inc. • 10/17/2025 03:45:00 PM
- XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. • GlobeNewswire Inc. • 10/02/2025 08:43:26 PM
- ESSA Pharma Inc. Amends Agreement with XenoTherapeutics • PR Newswire (US) • 09/24/2025 10:00:00 AM
- ESSA Pharma Inc. Amends Agreement with XenoTherapeutics • PR Newswire (Canada) • 09/24/2025 10:00:00 AM
- XOMA Royalty Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 09/22/2025 11:30:00 AM
- XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. • GlobeNewswire Inc. • 09/17/2025 01:00:00 PM
- XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2025 11:30:00 AM
- Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share • GlobeNewswire Inc. • 08/20/2025 12:49:14 PM
